Inovio Pharmaceuticals
VC Fund
Plymouth Meeting, United States
Inovio Pharmaceuticals is a VC fund in Plymouth Meeting focused on Health Care and Therapeutics. INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have clinically demonstrated that DNA medicine can be delivered directly into cells in the body via aproprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, demonstrated it destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 90% of anal cancer, and 69% of vulvar cancer.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Inovio Pharmaceuticals invests in
Stages Inovio Pharmaceuticals invests in
Countries Inovio Pharmaceuticals invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jacqueline Shea
|
|||
Laurent Humeau
|
|||
Michael Sumner
|
|||
|
Paul Fisher
|
|||
Peter Kies
|
|||
| See all 7 contacts → | |||
Investment Focus
Industry
- Health Care 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
- Pharmaceutical 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jacqueline Shea
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
|
Laurent Humeau
Chief Scientific Officer; Executive Vice President of Research, Engineering and Clinical Developments
|
Chief Scientific Officer; Executive Vice President of Research, Engineering and Clinical Developments | Total investments: 0 | Find email | |
|
Michael Sumner
Chief Medical Officer
|
Chief Medical Officer | Total investments: 0 | Find email | |
|
Paul Fisher
Director of Bioengineering
|
Director of Bioengineering | Total investments: 0 | Find email | |
|
Peter Kies
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $17M / Series A / Mar 24, 2022 | |
|
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $12M / Series A / Mar 03, 2021 | |
|
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $10.5M / Series A / Feb 21, 2019 |
Co-Investors
Sante Ventures
3 deals together
Korea Investment Partners
2 deals together
Flerie Invest
1 deal together
Global Bio Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Inovio Pharmaceuticals invest in?
Inovio Pharmaceuticals invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Inovio Pharmaceuticals?
Public channels for Inovio Pharmaceuticals include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Inovio Pharmaceuticals?
The team at Inovio Pharmaceuticals includes Jacqueline Shea (Chief Executive Officer), Laurent Humeau (Chief Scientific Officer; Executive Vice President of Research, Engineering and Clinical Developments) and Michael Sumner (Chief Medical Officer), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
